Study Reason 5 O O
adds Reason 5 O O
credibility Reason 5 O O
of Reason 5 O O
antiviral Reason 5 O O
effects Reason 5 O O
of Reason 5 O O
echinacea Reason 5 O O
extract Reason 5 O O
in Reason 5 O O
relation Reason 5 O O
to Reason 5 O O
Covid-19 Reason 5 O O
Five Reason 5 O O
months Reason 5 O O
of Reason 5 O O
supplementation Reason 5 O O
with Reason 5 O O
2,400 Reason 5 O O
mg Reason 5 O O
per Reason 5 O O
day Reason 5 O O
of Reason 5 O O
Echinaforce Reason 5 O O
(A.Vogel Reason 5 O O
AG, Reason 5 O O
Switzerland) Reason 5 O O
resulted Reason 5 O O
in Reason 5 O O
a Reason 5 O O
25% Reason 5 O O
reduction Reason 5 O O
of Reason 5 O O
all Reason 5 O O
respiratory Reason 5 O O
virus, Reason 5 O O
increasing Reason 5 O O
to Reason 5 O O
43% Reason 5 O O
for Reason 5 O O
enveloped Reason 5 O O
viruses Reason 5 O O
and Reason 5 O O
48% Reason 5 O O
for Reason 5 O O
coronavirus Reason 5 O O
infections Reason 5 O O
in Reason 5 O O
subjects, Reason 5 O O
according Reason 5 O O
to Reason 5 O O
data Reason 5 O O
published Reason 5 O O
in Reason 5 O O
Frontiers Reason 5 O O
in Reason 5 O O
Pharmacology. Reason 5 O O
A Reason 5 O O
99% Reason 5 O O
reduction Reason 5 O O
in Reason 5 O O
viral Reason 5 O O
loads Reason 5 O O
when Reason 5 O O
4,000 Reason 5 O O
mg Reason 5 O O
of Reason 5 O O
EF Reason 5 O O
was Reason 5 O O
administered Reason 5 O O
during Reason 5 O O
acute Reason 5 O O
RTI Reason 5 O O
episodes, Reason 5 O O
which Reason 5 O O
suggests Reason 5 O O
the Reason 5 O O
limited Reason 5 O O
ability Reason 5 O O
of Reason 5 O O
respiratory Reason 5 O O
viruses Reason 5 O O
to Reason 5 O O
evade Reason 5 O O
the Reason 5 O O
antiviral Reason 5 O O
effects Reason 5 O O
attributed Reason 5 O O
to Reason 5 O O
EF Reason 5 O O
extract, Reason 5 O O
wrote Reason 5 O O
the Reason 5 O O
researchers. Reason 5 O O
"A Reason 5 O O
commercial Reason 5 O O
preparation Reason 5 O O
of Reason 5 O O
Echinacea Reason 5 O O
purpurea Reason 5 O O
in Reason 5 O O
the Reason 5 O O
licensed Reason 5 O O
dosage Reason 5 O O
(Echinaforce Reason 5 O O
extract), Reason 5 O O
represents Reason 5 O O
a Reason 5 O O
safe, Reason 5 O O
easy-to-use Reason 5 O O
and Reason 5 O O
widely Reason 5 O O
available Reason 5 O O
cost-efficient Reason 5 O O
antiviral Reason 5 O O
with Reason 5 O O
effects Reason 5 O O
in Reason 5 O O
preventing Reason 5 O O
respiratory Reason 5 O O
tract Reason 5 O O
infections, Reason 5 O O
including Reason 5 O O
SARS-CoV2 Reason 5 O O
and Reason 5 O O
reducing Reason 5 O O
virus Reason 5 O O
load," Reason 5 O O
they Reason 5 O O
stated. Reason 5 O O
"It Reason 5 O O
may Reason 5 O O
add Reason 5 O O
well Reason 5 O O
to Reason 5 O O
existing Reason 5 O O
counter Reason 5 O O
measures Reason 5 O O
in Reason 5 O O
the Reason 5 O O
current Reason 5 O O
Covid-19 Reason 5 O O
pandemic Reason 5 O O
like Reason 5 O O
vaccinations, Reason 5 O O
social Reason 5 O O
distancing Reason 5 O O
and Reason 5 O O
wearing Reason 5 O O
protective Reason 5 O O
facemasks. Reason 5 O O
Future O O O O
confirmatory O O O O
studies O O O O
are O O O O
warranted." O O O O
The O O O O
study O O O O
was O O O O
funded O O O O
by O O O O
A.Vogel O O O O
AG. O O O O
Further O O O O
substantiation O O O O
for O O O O
the O O O O
inherent O O O O
preventative O O O O
qualities O O O O
of O O O O
the O O O O
herb O O O O
Commenting O O O O
independently O O O O
on O O O O
the O O O O
study' O O O O
findings, O O O O
Dr O O O O
Stefan O O O O
Gafner, O O O O
Chief O O O O
Science O O O O
Officer O O O O
at O O O O
the O O O O
American O O O O
Botanical O O O O
Council, O O O O
said O O O O
that O O O O
preventative O O O O
studies O O O O
can O O O O
be O O O O
difficult O O O O
to O O O O
interpret O O O O
and O O O O
limitations O O O O
in O O O O
the O O O O
current O O O O
trial O O O O
necessitate O O O O
further O O O O
testimony. O O O O
All O O O O
the O O O O
same, O O O O
results O O O O
conform O O O O
with O O O O
previous O O O O
findings O O O O
and O O O O
further O O O O
substantial O O O O
the O O O O
inherent O O O O
preventative O O O O
qualities O O O O
of O O O O
the O O O O
herb, O O O O
he O O O O
said. O O O O
"I O O O O
hope O O O O
manufacturers O O O O
may O O O O
take O O O O
a O O O O
closer O O O O
look O O O O
at O O O O
echinacea O O O O
as O O O O
an O O O O
ingredient, O O O O
and O O O O
possibly O O O O
invest O O O O
more O O O O
resources O O O O
into O O O O
clinical O O O O
studies, O O O O
which O O O O
may O O O O
lead O O O O
to O O O O
more O O O O
confidence O O O O
by O O O O
consumers O O O O
about O O O O
the O O O O
benefits O O O O
of O O O O
their O O O O
product O O O O
and O O O O
therefore O O O O
increased O O O O
sales." O O O O
Additional Reason 5 O O
options Reason 5 O O
Novel Reason 5 O O
pathogens, Reason 5 O O
like Reason 5 O O
Covid-19, Reason 5 O O
present Reason 5 O O
a Reason 5 O O
significant Reason 5 O O
threat Reason 5 O O
to Reason 5 O O
public Reason 5 O O
health, Reason 5 O O
with Reason 5 O O
vaccines Reason 5 O O
often Reason 5 O O
the Reason 5 O O
first Reason 5 O O
line Reason 5 O O
of Reason 5 O O
defence. Reason 5 O O
Messenger Reason 5 O O
RNA Reason 5 O O
and Reason 5 O O
vector-based Reason 5 O O
vaccines Reason 5 O O
were Reason 5 O O
credited Reason 5 O O
with Reason 5 O O
90% Reason 5 O O
effectiveness Reason 5 O O
in Reason 5 O O
preventing Reason 5 O O
infections, Reason 5 O O
progression Reason 5 O O
to Reason 5 O O
severe Reason 5 O O
illness, Reason 5 O O
and Reason 5 O O
transmission Reason 5 O O
of Reason 5 O O
SARS-CoV-2. Reason 5 O O
However, Reason 5 O O
recent Reason 5 O O
US Reason 5 O O
data Reason 5 O O
demonstrates Reason 5 O O
the Reason 5 O O
short-term Reason 5 O O
potency Reason 5 O O
of Reason 5 O O
Covid Reason 5 O O
vaccines Reason 5 O O
and Reason 5 O O
identified Reason 5 O O
a Reason 5 O O
sharp Reason 5 O O
decline Reason 5 O O
in Reason 5 O O
efficacity Reason 5 O O
after Reason 5 O O
eight Reason 5 O O
months, Reason 5 O O
along Reason 5 O O
with Reason 5 O O
marked Reason 5 O O
differences Reason 5 O O
between Reason 5 O O
vaccine Reason 5 O O
variants, Reason 5 O O
the Reason 5 O O
authors Reason 5 O O
stated. Reason 5 O O
"Additional Reason 5 O O
options Reason 5 O O
are Reason 5 O O
urgently Reason 5 O O
needed Reason 5 O O
to Reason 5 O O
effectively Reason 5 O O
attenuate Reason 5 O O
non-severe Reason 5 O O
infections Reason 5 O O
and Reason 5 O O
naso-oropharyngeal Reason 5 O O
virus Reason 5 O O
concentrations Reason 5 O O
in Reason 5 O O
order Reason 5 O O
to Reason 5 O O
further Reason 5 O O
contain Reason 5 O O
viral Reason 5 O O
dissemination," Reason 5 O O
they Reason 5 O O
said. Reason 5 O O
Echinacea O O O O
exhibits O O O O
broad O O O O
antiviral O O O O
effects, O O O O
including O O O O
for O O O O
coronaviruses O O O O
in O O O O
both O O O O
adults O O O O
and O O O O
children, O O O O
and O O O O
particularly O O O O
formulations O O O O
containing O O O O
fresh O O O O
Echinacea O O O O
purpurea O O O O
that O O O O
reduces O O O O
inflammatory O O O O
cytokines O O O O
while O O O O
increasing O O O O
anti-inflammatory O O O O
cytokines O O O O
that O O O O
respond O O O O
to O O O O
invading O O O O
pathogens. O O O O
Three-cycle O O O O
design O O O O
The O O O O
study O O O O
took O O O O
place O O O O
during O O O O
the O O O O
Covid-19 O O O O
pandemic O O O O
to O O O O
investigate O O O O
the O O O O
antiviral O O O O
effects O O O O
of O O O O
EF O O O O
on O O O O
120 O O O O
healthy O O O O
volunteers. O O O O
Subjects O O O O
endured O O O O
three O O O O
prevention O O O O
cycles O O O O
(two O O O O
lasting O O O O
two O O O O
months O O O O
and O O O O
the O O O O
third O O O O
one O O O O
month) O O O O
and O O O O
were O O O O
treated O O O O
with O O O O
2,400mg O O O O
of O O O O
EF O O O O
extract O O O O
daily. O O O O
Tablets O O O O
contained O O O O
400mg O O O O
of O O O O
an O O O O
hydroethanolic O O O O
extract O O O O
of O O O O
Echinacea O O O O
purpurea O O O O
(95% O O O O
external O O O O
plant O O O O
and O O O O
5% O O O O
root). O O O O
All O O O O
volunteers O O O O
were O O O O
Caucasian O O O O
with O O O O
a O O O O
mean O O O O
age O O O O
of O O O O
36 O O O O
years. O O O O
None O O O O
had O O O O
been O O O O
vaccinated O O O O
against O O O O
Covid-19 O O O O
at O O O O
study O O O O
baseline; O O O O
three O O O O
received O O O O
a O O O O
first O O O O
SARS-CoV-2 O O O O
dose O O O O
towards O O O O
the O O O O
end O O O O
the O O O O
first O O O O
phase, O O O O
and O O O O
12 O O O O
had O O O O
completed O O O O
the O O O O
vaccine O O O O
programme O O O O
by O O O O
the O O O O
study O O O O
end. O O O O
Subjects O O O O
had O O O O
to O O O O
provide O O O O
naso/orophyaryngeal O O O O
(NP/OP) O O O O
swaps O O O O
and O O O O
blood O O O O
samples O O O O
on O O O O
a O O O O
monthly O O O O
basis O O O O
- O O O O
and O O O O
on O O O O
days O O O O
one, O O O O
two, O O O O
five O O O O
and O O O O
10 O O O O
during O O O O
acute O O O O
symptomatic O O O O
episodes O O O O
- O O O O
for O O O O
virus O O O O
detection O O O O
and O O O O
quantification, O O O O
and O O O O
also O O O O
completed O O O O
a O O O O
symptom O O O O
diary O O O O
to O O O O
establish O O O O
severity O O O O
of O O O O
respiratory O O O O
symptoms. O O O O
Samples O O O O
identified O O O O
21 O O O O
and O O O O
29 O O O O
positive O O O O
cases O O O O
of O O O O
any O O O O
virus O O O O
in O O O O
the O O O O
EF O O O O
and O O O O
control O O O O
group, O O O O
of O O O O
which O O O O
five O O O O
and O O O O
14 O O O O
samples O O O O
tested O O O O
SARS-CoV2 O O O O
positive. O O O O
Acute O O O O
RTI O O O O
episodes O O O O
were O O O O
treated O O O O
with O O O O
800mg O O O O
EF O O O O
extract O O O O
(4,000 O O O O
mg/day) O O O O
five O O O O
times O O O O
daily, O O O O
for O O O O
up O O O O
to O O O O
10 O O O O
days. O O O O
The O O O O
control O O O O
group O O O O
was O O O O
observed O O O O
in O O O O
parallel O O O O
for O O O O
the O O O O
same O O O O
period. O O O O
Strong O O O O
risk O O O O
reductions O O O O
EF O O O O
treatment O O O O
during O O O O
acute O O O O
episodes O O O O
significantly O O O O
reduced O O O O
overall O O O O
virus O O O O
load O O O O
and O O O O
the O O O O
time O O O O
to O O O O
clearance O O O O
for O O O O
all O O O O
viruses O O O O
(eight O O O O
days) O O O O
and O O O O
SARS-CoV-2 O O O O
(just O O O O
under O O O O
five O O O O
days), O O O O
relative O O O O
to O O O O
baseline. O O O O
The O O O O
number O O O O
of O O O O
fever O O O O
days O O O O
also O O O O
reduced O O O O
but O O O O
not O O O O
overall O O O O
symptom O O O O
severity, O O O O
and O O O O
there O O O O
were O O O O
fewer O O O O
hospitalisations O O O O
in O O O O
the O O O O
intervention O O O O
group. O O O O
Both O O O O
groups O O O O
took O O O O
other O O O O
medications O O O O
during O O O O
RTI O O O O
episodes, O O O O
but O O O O
instances O O O O
were O O O O
higher O O O O
among O O O O
the O O O O
control O O O O
group, O O O O
which O O O O
the O O O O
researchers O O O O
say O O O O
may O O O O
have O O O O
masked O O O O
the O O O O
effects O O O O
of O O O O
EF O O O O
treatment O O O O
on O O O O
symptom O O O O
level. O O O O
The O O O O
strongest O O O O
risk O O O O
reductions O O O O
for O O O O
RTI O O O O
(63%) O O O O
were O O O O
associated O O O O
with O O O O
SARS-CoV2 O O O O
viruses, O O O O
although O O O O
the O O O O
authors O O O O
warn O O O O
against O O O O
over O O O O
interpretation O O O O
as O O O O
clinical O O O O
significance O O O O
"was O O O O
only O O O O
attained O O O O
for O O O O
the O O O O
prevention O O O O
of O O O O
coronaviruses, O O O O
and O O O O
for O O O O
SARS-CoV-2". O O O O
"We O O O O
did O O O O
not O O O O
monitor O O O O
the O O O O
use O O O O
of O O O O
non-pharmaceutical O O O O
interventions O O O O
(NPIs) O O O O
during O O O O
the O O O O
study O O O O
and O O O O
the O O O O
impact O O O O
of O O O O
this O O O O
potential O O O O
confounder O O O O
remains O O O O
questionable," O O O O
they O O O O
wrote. O O O O
Conclusion Reason 5 O O
Findings Reason 5 O O
add Reason 5 O O
further Reason 5 O O
credibility Reason 5 O O
to Reason 5 O O
the Reason 5 O O
antiviral Reason 5 O O
effects Reason 5 O O
of Reason 5 O O
EF Reason 5 O O
in Reason 5 O O
preventing Reason 5 O O
RTI Reason 5 O O
viruses, Reason 5 O O
including Reason 5 O O
SARS-CoV2, Reason 5 O O
said Reason 5 O O
the Reason 5 O O
researchers. Reason 5 O O
"Immune Reason 5 O O
modulation Reason 5 O O
instead Reason 5 O O
of Reason 5 O O
immune-stimulation Reason 5 O O
can Reason 5 O O
allow, Reason 5 O O
if Reason 5 O O
necessary, Reason 5 O O
a Reason 5 O O
prolonged Reason 5 O O
preventive Reason 5 O O
use Reason 5 O O
of Reason 5 O O
this Reason 5 O O
extract, Reason 5 O O
to Reason 5 O O
exploit Reason 5 O O
its Reason 5 O O
potential Reason 5 O O
ability Reason 5 O O
to Reason 5 O O
reduce Reason 5 O O
viral Reason 5 O O
loads." Reason 5 O O
Furthermore, Reason 5 O O
by Reason 5 O O
substantially Reason 5 O O
reducing Reason 5 O O
virus Reason 5 O O
loads Reason 5 O O
in Reason 5 O O
infected Reason 5 O O
subjects, Reason 5 O O
EF Reason 5 O O
offers Reason 5 O O
"a Reason 5 O O
supportive Reason 5 O O
addition Reason 5 O O
to Reason 5 O O
existing Reason 5 O O
mandated Reason 5 O O
treatments Reason 5 O O
like Reason 5 O O
vaccinations". Reason 5 O O
Source: O O O O
Frontiers O O O O
of O O O O
Pharmacology O O O O
10.3389/fphar.2022.856410 O O O O
](https://doi.org/10.3389/fphar.2022.856410) O O O O
'Echinacea O O O O
Purpurea O O O O
For O O O O
the O O O O
Long-Term O O O O
Prevention O O O O
of O O O O
Viral O O O O
Respiratory O O O O
Tract O O O O
Infections O O O O
During O O O O
Covid-19 O O O O
Pandemic: O O O O
A O O O O
Randomized, O O O O
Open, O O O O
Controlled, O O O O
Exploratory O O O O
Clinical O O O O
Study' O O O O
Authors: O O O O
E. O O O O
Kolev, O O O O
et O O O O
al O O O O
